SABS

SAB Biotherapeutics Inc

SABS, USA

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

https://www.sabbiotherapeutics.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SABS
stock
SABS

12 Health Care Stocks Moving In Monday's After-Market Session Benzinga

Read more →
SABS
stock
SABS

SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at ATTD-Asia Conference 2025 Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$8.8333

Analyst Picks

Strong Buy

4

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.80

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

3.23 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.91 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.11

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 22.87% of the total shares of SAB Biotherapeutics Inc

1.

Bvf Inc

(8.8159%)

since

2025/06/30

2.

Sessa Capital IM LP

(4.4036%)

since

2025/06/30

3.

Vanguard Group Inc

(2.7122%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.1861%)

since

2025/07/31

5.

Geode Capital Management, LLC

(0.8142%)

since

2025/06/30

6.

A4Investments SICAV SIF ACCI IlanaA2EURH

(0.5763%)

since

2025/08/31

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.494%)

since

2025/07/31

8.

Pathstone Holdings LLC

(0.4865%)

since

2025/06/30

9.

Fidelity Extended Market Index

(0.4138%)

since

2025/07/31

10.

Kovitz Investment Group Partners, LLC

(0.1844%)

since

2025/06/30

11.

First Premier Bank

(0.1824%)

since

2025/06/30

12.

Citadel Advisors Llc

(0.1642%)

since

2025/06/30

13.

Fidelity Total Market Index

(0.1239%)

since

2025/07/31

14.

Kestra Advisory Services, LLC

(0.1146%)

since

2025/06/30

15.

Creative Planning Inc

(0.1138%)

since

2025/06/30

16.

Northern Trust Corp

(0.1094%)

since

2025/06/30

17.

Renaissance Technologies Corp

(0.1059%)

since

2025/06/30

18.

UBS Group AG

(0.1024%)

since

2025/06/30

19.

Fidelity Series Total Market Index

(0.102%)

since

2025/07/31

20.

Spartan Extended Market Index Pool F

(0.0886%)

since

2025/07/31

21.

NT Ext Equity Mkt Idx Fd - L

(0.083%)

since

2025/06/30

22.

Northern Trust Extended Eq Market Idx

(0.083%)

since

2025/06/30

23.

BlackRock Inc

(0.0673%)

since

2025/06/30

24.

Advisor Group Holdings, Inc.

(0.0474%)

since

2025/06/30

25.

Fidelity Nasdaq Composite Index

(0.0474%)

since

2025/07/31

26.

Spartan Total Market Index Pool G

(0.0445%)

since

2025/07/31

27.

Extended Equity Market Fund K

(0.0427%)

since

2025/06/30

28.

Sachetta LLC

(0.0394%)

since

2025/06/30

29.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0234%)

since

2025/06/30

30.

NT Ext Equity Mkt Idx Fd - NL

(0.0216%)

since

2025/06/30

31.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0198%)

since

2024/12/31

32.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0168%)

since

2025/06/30

33.

Vanguard U.S. Eq Idx £ Acc

(0.0109%)

since

2025/07/31

34.

State St US Extended Mkt Indx NL Cl C

(0.0105%)

since

2025/08/31

35.

Tower Research Capital LLC

(0.007%)

since

2025/06/30

36.

Extended Equity Market Fund M

(0.0054%)

since

2025/06/30

37.

Northern Trust Wilshire 5000

(0.0048%)

since

2025/06/30

38.

Mccormack Advisors International

(0.0021%)

since

2025/06/30

39.

Gs Investment Inc

(0.0019%)

since

2025/06/30

40.

Morgan Stanley - Brokerage Accounts

(0.0016%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.5

EPS Estimate

-0.4583

EPS Difference

0.9583

Surprise Percent

209.0988%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.